# Kyverna Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kyverna-therapeutics

- Industry: Biotechnology
- Headquarters: Emeryville, US
- Website: www.kyvernatx.com
- Total disclosed funding: $167M
- Latest round: Series B (Aug 3, 2023)
- Investors on record: 15

## About

Founded in 2018 by founder Jeffrey Greve, and based in California, US, Kyverna Therapeutics, Inc. is a biotechnology company that operates a cell therapy platform. In October 2025, Kyverna Therapeutics, Inc. raised USD 150 million in venture debt funding from investor Oxford Finance. The facility includes an initial tranche of USD 40 million and two additional tranches totaling USD 60 million, subject to the satisfaction of certain terms and conditions of the loan and security agreement. A fourth tranche of USD 50 million may also be made available subject to Oxford Finance’s discretion. As of November 2025, the company is led by CEO Warner Biddle.

Kyverna Therapeutics researches and develops cell therapies for patients with autoimmune diseases. As of 2024, the company’s product portfolio includes KYV-101, a CAR (chimeric antigen receptor) T-cell therapy undergoing clinical trials to treat diseases such as multiple sclerosis, myasthenia gravis, systemic sclerosis, and lupus nephritis. The treatment functions by resetting the immune system and targeting B cell-driven haematological malignancies to treat rheumatology and neurology-based autoimmune diseases.

## Funding rounds

- Series B, Aug 3, 2023, $60M — Insight Partners, Gilead Sciences, Inc., jVen Capital, CAM Capital, RTW Investments, LYFE Capital, Vida Ventures, Northpond Ventures, Westlake Village BioPartners, Bain Capital Life Sciences, GordonMD Global Investments
- Series B, Jan 26, 2022, $85M — Insight Partners, Argentum, Hudson Bay Capital, Gilead Sciences, Inc., HealthCor Group, jVen Capital, CAM Capital, RTW Investments, Intellia Therapeutics, Inc., LYFE Capital, Vida Ventures, Northpond Ventures, Westlake Village BioPartners
- Series A, Jan 10, 2020, $22M — Gilead Sciences, Inc., Vida Ventures, Westlake Village BioPartners

## Investors

- Gilead Sciences, Inc. — Series A, Series B
- Vida Ventures (https://capitalatlas.ai/funds/vida-ventures) — Series A, Series B
- Westlake Village BioPartners (https://capitalatlas.ai/funds/westlake-village-biopartners) — Series A, Series B
- Insight Partners (https://capitalatlas.ai/funds/insight-partners) — Series B
- Argentum (https://capitalatlas.ai/funds/argentum) — Series B
- Hudson Bay Capital — Series B
- HealthCor Group (https://capitalatlas.ai/funds/healthcor-group) — Series B
- jVen Capital (https://capitalatlas.ai/funds/jven-capital) — Series B
- CAM Capital — Series B
- RTW Investments (https://capitalatlas.ai/funds/rtw-investments) — Series B
- Intellia Therapeutics, Inc. — Series B
- LYFE Capital — Series B
- Northpond Ventures (https://capitalatlas.ai/funds/northpond-ventures) — Series B
- Bain Capital Life Sciences — Series B
- GordonMD Global Investments (https://capitalatlas.ai/funds/gordonmd-global-investments) — Series B